Please use this identifier to cite or link to this item: https://libjncir.jncasr.ac.in/xmlui/handle/10572/805
Full metadata record
DC FieldValueLanguage
dc.contributor.advisorRanga, Udaykumar-
dc.contributor.authorDash, Prasanta Kumar-
dc.date.accessioned2012-09-07T10:35:19Z-
dc.date.available2012-09-07T10:35:19Z-
dc.date.issued2007-
dc.identifier.citationDash, Prasanta Kumar. 2007, Isolation and biological characterization of infectious molecular clones of HIV-1 subtype-C with expanded coreceptor usage from an Indian demented subject, Ph.D thesis, Jawaharlal Nehru Centre for Advanced Scientific Research, Bengaluruen_US
dc.identifier.urihttps://libjncir.jncasr.ac.in/xmlui/10572/805-
dc.description.abstractTwenty five years following its discovery, Human Immunodeficiency Virus (HIV) - the causative agent of Acquired Immuno Deficiency Syndrome (AIDS), still remains a major threat to human beings. The most widely recognized consequence of HIV-1 infection is the slow and progressive deterioration of the integrity and function of the immune system. Although the clinical presentation of HIV-1-associated immune system dysfunction varies from individual to individual, the infection, without therapeutic intervention, generally unfolds in three phases over a period of approximately six to ten years after initial exposure to the virus: acute infection (lasting approximately three months), clinical latency (lasting typically eight to ten years), and clinically apparent disease (lasting two to three years) (Pantaleo, G et al., 1993). The acute phase is characterized by a large, but transient viremia within the peripheral circulation and sometimes an acute mononucleosis-like syndrome. During clinical latency, there is a slow but steady decline in the number of CD4-positive T lymphocytes and in the general integrity of the immune system, a very low level of detectable virus within the peripheral blood, and a concurrent decrease in the titer of antiviral antibodies (Pantaleo, G et al., 1993). During this period, HIV-1 replication is readily detectable in the lymph nodes despite almost undetectable levels of plasma virus (Pantaleo, G et al., 1993, 1991, Embretson, J et al., 1993). The clinically apparent phase of disease is typified by the reappearance of HIV-1 viremia, a precipitous loss of CD4-positive T lymphocytes, a rapid decline in immune function, and numerous AIDS-defining illnesses (Katzenstein DA et al., 1996). Although the rate of the disease progression is highly variable among HIV patients, most infections follow a typical course that can be divided into three stages. Primary HIV-infection, clinical latency, and clinically apparent disease as described above and as shown in Figure1.1. Without pharmacotherapeutic intervention, the ultimate outcome of this phase is death for a vast majority of infected individuals.-
dc.language.isoEnglishen_US
dc.publisherJawaharlal Nehru Centre for Advanced Scientific Researchen_US
dc.rights© 2007 JNCASRen_US
dc.subjectMolecular clones of HIV-1en_US
dc.subjectMolecular Biologyen_US
dc.titleIsolation and biological characterization of infectious molecular clones of HIV-1 subtype-C with expanded coreceptor usage from an Indian demented subjecten_US
dc.typeThesisen_US
dc.type.qualificationlevelDoctoralen_US
dc.type.qualificationnamePh.D.en_US
dc.publisher.departmentMolecular Biology and Genetics Unit (MBGU)en_US
Appears in Collections:Student Theses (MBGU)

Files in This Item:
File Description SizeFormat 
5097.pdf
  Restricted Access
2.8 MBAdobe PDFView/Open Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.